Addex Therapeutics Ltd ADXN:NASDAQ

RT Quote | Last NYSE Arca, VOL From CTA | USD
after hours iconAfter Hours: Last | 07/01/22 EDT
1.21quote price arrow up+0.02 (+1.68%)
Volume
717
Close
1.19quote price arrow up+0.04 (+3.48%)
Volume
53,704
52 week range
1.03 - 10.90
Loading...
  • Open1.21
  • Day High1.22
  • Day Low1.12
  • Prev Close1.15
  • 52 Week High10.90
  • 52 Week High Date07/01/21
  • 52 Week Low1.03
  • 52 Week Low Date06/29/22

Key Stats

  • Market Cap7.51M
  • Shares Out6.31M
  • 10 Day Average Volume0.15M
  • Dividend-
  • Dividend Yield-
  • Beta2.07
  • YTD % Change-81.08

KEY STATS

  • Open1.21
  • Day High1.22
  • Day Low1.12
  • Prev Close1.15
  • 52 Week High10.90
  • 52 Week High Date07/01/21
  • 52 Week Low1.03
  • 52 Week Low Date06/29/22
  • Market Cap7.51M
  • Shares Out6.31M
  • 10 Day Average Volume0.15M
  • Dividend-
  • Dividend Yield-
  • Beta2.07
  • YTD % Change-81.08

RATIOS/PROFITABILITY

  • EPS (TTM)-
  • P/E (TTM)-
  • Fwd P/E (NTM)-
  • EBITDA (TTM)-
  • ROE (TTM)-
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date-
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Addex Therapeutics Ltd

There is no recent news for this security.

Profile

MORE
Addex Therapeutics Ltd is a Switzerland-based clinical-stage pharmaceutical company. The Company focuses on development and commercialization of orally available small molecule drugs known as allosteric modulators for neurological disorders. The Company’s clinical programs pipeline include dipraglurant (mGlu5 NAM), which is Phase 2a placebo-controlled clinical trial for Parkinson's disease levodopa-induced dyskinesia (PD-LID), and is being prepared to enter registration...
Vincent Lawton
Independent Non-Executive Chairman of the Board of Directors
Tim Dyer
Chief Executive Officer, Member of the Executive Management, Member of the Board of Directors
Address
Chemin des Mines, 9
Plan-les-ouates
1202
Switzerland